D-Alanine Phosphoramidate Pronucleotides for HCV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infections lack effective and low-toxicity pharmaceutical agents, necessitating the development of new compounds that can target liver diseases and flavivirus infections with high efficacy and bioavailability.
Innovation Solution
D-Alanine phosphoramidate halogeno pyrimidine nucleoside analogs are developed, which accumulate favorably in liver cells and are administered alone or in combination with other anti-HCV agents to treat HCV infections and related liver conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for HCV infections are used, then treatment coverage is provided, but efficacy and bioavailability are insufficient
Solution Approach 1:
The patent modifies the chemical structure of nucleoside analogs by incorporating D-amino acid phosphoramidate groups and halogeno pyrimidine moieties, changing physical and chemical parameters to achieve both high efficacy and bioavailability simultaneously
Solution Approach 2:
The invention creates composite molecular structures combining nucleoside backbones with phosphoramidate and halogeno pyrimidine components, where the synergistic interaction of different molecular elements produces enhanced therapeutic effects and improved pharmacokinetic properties
2Reliability
If new pharmaceutical agents are developed to improve efficacy, then treatment effectiveness increases, but toxicity to the host may increase
Solution Approach 1:
The patent introduces specific halogen substitutions at particular positions on the pyrimidine ring and uses D-amino acid configurations to create localized molecular features that enhance antiviral activity while maintaining selective toxicity profiles
Solution Approach 2:
The use of D-amino acid phosphoramidate prodrugs creates transient molecular forms that are metabolized to active compounds in vivo, providing potent antiviral effects temporarily while avoiding long-term accumulation and chronic toxicity
3Reliability
If D-Alanine phosphoramidate halogeno pyrimidine nucleoside analogs are used, then tissue levels and efficacy are improved, but compound complexity increases
Solution Approach 1:
The patent divides the molecular structure into distinct functional segments: the nucleoside backbone, the phosphoramidate linker, and the halogeno pyrimidine head group, where each segment contributes specific properties that collectively achieve high tissue levels without requiring overall molecular complexity
Data Source
AI summary
Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.